Log In
Print
BCIQ
Print
Print this Print this
 

Veregen, sinecatechins (SB03) (formerly Polyphenon E)

  Manage Alerts
Collapse Summary General Information
Company Mitsui & Co. Ltd.
DescriptionTopical formulation of polyphenols extracted from green tea leaves
Molecular Target Unknown
Mechanism of ActionUnknown
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationGenital warts
Indication DetailsTreat external genital and perianal warts; Treat genital warts; Treat genital warts caused by human papillomavirus (HPV)
Regulatory Designation Canada - Standard Review (Treat genital warts)
Partner Abbott Laboratories; Azanta A/S; Bial-Portela & Ca. S.A.; Eczacibasi Group; Endo International plc; Epitome Pharmaceuticals Ltd.; Medigene AG; Nordic Group; SynCore Biotechnology Co. Ltd.; Will-Pharma

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

16

$3.0M

0

$12.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today